Indivior Pharmaceuticals
INDV
116 hedge funds and large institutions have $867M invested in Indivior Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 42 reducing their positions, and 21 closing their positions.
554% more call options, than puts
Call options by funds: $962K | Put options by funds: $147K
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
11.28% more ownership
Funds ownership: 62% → 73.27% (+11%)
3% more funds holding
Funds holding: 113 → 116 (+3)
11% less capital invested
Capital invested by funds: $975M → $867M (-$108M)
19% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 42
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$43.3M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$28.3M |
| 3 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
+$23.9M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$22.8M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$29.8M |
| 2 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
-$17M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
-$11.5M |
| 4 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$9.45M |
| 5 |
Citigroup
New York
|
-$9.04M |
INDV Hedge Fund Activity: Q1 2025 in Review
116 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q1 2025, worth a combined $867M — down 11% from $975M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new INDV positions and 21 closed out — a net gain of 3 holders — while 34 added to existing stakes and 42 trimmed.
The largest buyer was Madison Avenue Partners, adding an estimated $43.3M. The largest seller was Morgan Stanley, cutting an estimated $29.8M.
- 116 institutional investors held Indivior Pharmaceuticals (INDV) as of Q1 2025, up from 113 in Q4 2024.
- Funds reported $867M of Indivior Pharmaceuticals stock for Q1 2025, down 11% quarter-over-quarter.
- 24 funds opened new Indivior Pharmaceuticals positions in Q1 2025 and 21 closed out, a net change of +3 holders.
- The largest Indivior Pharmaceuticals buyer in Q1 2025 was Madison Avenue Partners, an estimated $43.3M added.
- The largest Indivior Pharmaceuticals seller in Q1 2025 was Morgan Stanley, an estimated $29.8M sold.
Based on aggregated 13F filings for Q1 2025.